CD81 and acute myeloid leukemia: Molecules selectively targeting CD81 could be of prime interest to treat different onco-malignancies, including B-cell and mantle cell lymphomas [21,22], acute lymphoblastic leukemia (ALL) [23] and perhaps AML.